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Different aspects of PLC-mediated signalling have been covered in a number of excellent reviews that focus, for example, on the catalytic mechanism [7] , regulatory interactions and physiological roles of PLC families [1] [2] [3] [4] [5] or on structural and mechanistic aspects of regulation [8] [9] [10] . In this review, we highlight recent experimental evidence related to the dysfunction of PLCγ enzymes and links to disease, based on genetic and genomic analysis of animal models and patients; we further discuss the molecular mechanisms that underpin dysfunction. These recent findings, supporting a connection between PLCγ variants harbouring key, gain-offunction mutations and disease development, provide a new perspective for the role of PLC enzymes in various disorders and underscore their importance as therapeutic targets.
Mutations in PLCγ enzymes and disease development
The discovery of putative disease-causing mutations in PLCγ enzymes (Tables 1 and   2 ) reflects a surge in genetic and genomic investigations that has been facilitated by the development of massively parallel, high-throughput, next-generation sequencing [11, 12] . Germline mutations in PLCγ have emerged as the cause of certain immune disorders, and somatic mutations have been identified as drivers of some types of cancer.
PLCγ mutations in immune diseases
The first link between PLCγ2 and immune diseases was established in the context of a large-scale ENU (N-ethyl-N-nitrosourea) mutagenesis screen, in which gain-offunction mutations were identified (Table 1) . Two mouse strains with limb defects, abnormal limb 5 and 14 (Ali5 and Ali14) were found to harbour single amino acid replacements in PLCγ2, leading to severe autoinflammatory disease [13] [14] [15] .
More recently, genetic analyses revealed the role of PLCγ2 in dominantly inherited human immune disorders (Table 1) . Germline deletion mutations were identified in three families with multiple cases of complex immune disease, designated as PLAID (PLCG2-associated antibody deficiency and immune dysregulation) [16] . These mutations, resulting in constitutive PLC activation, diminished downstream signalling.
Both Ca
2+ flux and extracellular signal-regulated kinase (ERK) phosphorylation were reduced in B cells. NK cells showed reduced Ca 2+ flux and reduced degranulation, while Ca 2+ flux in T-cells was normal. These downstream effects were unexpected given the gain of enzymatic function; however, they might be the result of local PIP 2 depletion or of feedback inhibition leading to down-regulation of distal signalling pathways. This complex downstream signalling output is also reflected by the presence of both autoimmune disorder and immune dysfunctions in patients with these mutations. Moreover, reduced temperatures alter the signalling downstream of PLCγ2 at the cellular level in these patients, triggering degranulation of mast cells;
this results in the condition known as cold-induced urticaria.
Another genetic study of an inherited immune disease identified S707Y substitution in PLCγ2; the associated disease was designated as APLAID (autoinflammatory PLAID) [17] . Discovery of the causal mutation was not amenable to linkage analysis and required whole exome sequencing of the germline of individuals from the affected family (Table 1) . APLAID patients do not suffer from cold-induced urticaria, and autoinflammatory disease is more pronounced than immune dysfunction. In contrast to cells with PLCγ2 deletions, the S707Y substitution not only leads to a gain of enzymatic function but also to increased downstream signalling, specifically Ca 2+ flux and ERK phosphorylation in B cells [17] . Possibly, the smaller increase in PLCγ2 activity, relative to the PLAID-causing deletion, that is caused by the point mutation might not be sufficient to trigger a negative feedback mechanism. One common manifestation for both disorders is the absence of class-switched memory B-cells; however, this is probably the result of distinct downstream signalling effects.
PLCγ mutations in cancer
PLCγ enzymes contribute to some oncogenic signalling pathways through signal 
Structural and mechanistic aspects of PLCγ function and mechanisms of deregulation
A large number of studies related to regulatory interactions of PLCγ enzymes identified tyrosine phosphorylation of PLCγ as the major mechanism of activation.
Some other, phosphorylation-independent mechanisms, such as activation of PLCγ2
by Rac, were also revealed (Box 1). However, it was only recently that sufficient structural information became available that would allow understanding of deregulation at the molecular level (Figures 1 and 2 ).
Structural basis of auto-inhibition and activation of PLCγ proteins
Understanding the molecular mechanisms underlying auto-inhibition and activation of PLCγ isoforms has been an intense area of research for over 20 years. Early work, focussing on the differences between PLCγ, δ and β regulation, determined that Despite these advances, the precise molecular basis of auto-inhibition and activation and importantly the amino acid residues crucial for these phenomena were unknown due to the lack of critical structural information, in particular related to the full-length PLCγ molecule and unique γSA (depicted in Figure 1A , top panel). Generating an Xray crystallographic structure proved challenging due to the inherent flexibility in various regions of the protein. Nevertheless, other techniques are available that have provided insight into the structural arrangements of the γSA and its interactions with the core. For instance, a combination of nuclear magnetic resonance (NMR), small angle X-ray scattering (SAXS), crystallography (of fragments of the protein), isothermal titration calorimetry (ITC) and modelling were utilised to study PLCγ1 [29] .
Previous studies that highlighted the sole importance of Y 783 in PLCγ1 activation were confirmed. Furthermore, NMR spectroscopy showed that the spPH, nSH2 and src-homology three (SH3) domains made few interactions with each other in the γSA.
By contrast, comparing the cSH2 spectrum with the γSA spectrum suggested that there are dynamic interactions between cSH2 and the other domains and linkers within γSA. Upon further analysis of tandem γSA fragments (cSH2-spPH), compared to isolated domains, it was clear that cSH2 and spPH have a transient interaction.
SAXS, a method that provides low-resolution structures of proteins in solution, was performed on the γSA, a number of tandem domains within the γSA and various tagged and complexed constructs [29] . Taking into account the SAXS and NMR data, a model was generated representing a possible average structural arrangement of the γSA, in which the spPH and cSH2 occupy the central lobe with nSH2 and SH3 peripheral to them ( Figure 1A , bottom panel).
PLCγ activation through the interaction between cSH2 and pY 783 has been known for some time, having been established through various lines of evidence. However, the crystal structure of phosphorylated tandem nSH2-cSH2, showing that residues 781 to 790 bound in cis to the canonical cSH2 pY peptide binding pocket, was obtained only recently [29] . linker in the cSH2 binding site [29] . The decreased affinity of phosphorylated γSA and full length PLCγ for FGFR1 was also reported using a pull-down assay. The intriguing possibility that phosphorylated PLCγ has a lower affinity for RTK than unphosphorylated PLCγ suggests that many PLCγ molecules can be phosphorylated by a single RTK. This would lead to greater signal amplitude than if the PLCγ remained engaged with the RTK.
Confirmation that the cSH2 is the domain in γSA directly involved in auto-inhibition came from NMR titration experiments [29] . The PLC-core from PLCγ was added independently into 15 N labelled domains of nSH2, cSH2 and spPH. An interaction could be measured only between the core and the cSH2 domain and this could be reversed through subsequent addition of the pY 783 linker. Importantly, this approach also revealed which surface of the cSH2 domain is in contact with the catalytic core of PLCγ and showed that this surface overlaps with the binding surface of the pY 783 linker. ITC with mutated cSH2 and/or core polypeptides confirmed that the following residues are important at the cSH2/core interface: R748, R753, N728, S729 and D1019. Introducing substitutions in these residues into full length PLCγ and assaying for PLC activity in cells also showed that disrupting the cSH2/core interface imparted increased basal activity and increased EGF stimulated activity compared to wild type protein [29] . Therefore, a clearer picture of the molecular basis of auto-inhibition and activation emerges from these data ( Figure 1B ). In the basal state, the low PLCγ catalytic activity is maintained through a specific interaction between the cSH2 domain and residues surrounding the active site. Phosphorylation at Y783 creates a binding site for the cSH2 domain that is of greater affinity than its binding site at the core. With the cSH2 occlusion removed from the active site the protein can now access its substrate in the membrane.
Structural basis of dysfunction
The structural basis of auto-inhibition and activation provides a useful framework for interpretation of the effects of various mutations and brings together observations from mouse models and human diseases, including immune disorders and cancer ( Figure 2 ). Given that the cSH2 domain was found to form an autoinhibitory interface with the catalytic domain, it is not surprising that the partial or complete deletion of this domain, as it is the case in PLAID patients, leads to a constitutively active PLCγ2 enzyme ( Figure 2 ). The mechanism of auto-inhibition also explains some of the more subtle disease-associated mutations; for instance the S707Y substitution found in APLAID patients, disturbs the autoinhibitory interface between cSH2 and the catalytic domain, which was confirmed by NMR and ITC studies [29] . The effect of this mutation on the enzymatic activity is less pronounced than for cSH2 deletions. This S707Y mutation is also an example of a point mutation that was found in both immune disease and cancer; recently, some patients with ibrutinib-resistant CLL were found to harbour this mutation, either in isolation or in combination with other PLCγ2 mutations and/or a C481S mutation in Bruton's tyrosine kinase, the target of ibrutinib [22] . Our understanding of the functional effect of these mutations can also be transferred to a recently discovered PLCγ1 point mutation that results in the substitution R707Q in angiosarcoma. R707Q (not to be confused with S707Y in PLCγ2) is located within the beta-sheet of the cSH2 domain. A destabilization of cSH2 structure, leading to a gain of enzymatic function by a similar mechanism, seems likely [20] . The PLCγ2 substitution R665W, found in ibrutinib-resistant CLL samples, is also located in the cSH2 domain [22] . Residue R665 in PLCγ2
(equivalent to PLCγ1 R687) is spatially close to PLCγ1 residue R707 mutated in angiosarcoma. However, it is more surface-exposed than the latter; therefore, it is not yet clear how its activating effect occurs.
Other mutations directly affecting PLCγ autoinhibition affect the ridge region of the catalytic domain ( Figure 2 ). For instance, mice with the ALI5 phenotype harbour the substitution D993L in PLCγ2, which leads to only a small increase in basal PLCγ activity; however, the activity following stimulation is greatly enhanced compared to the wild type [13, 15] . ITC, NMR and surface plasmon resonance experiments suggest that the reason for the higher activity in cells is the disruption of the autoinhibitory interface between the catalytic domain and the cSH2 domain, combined with enhanced membrane recruitment [15, 29] . The PLCγ1 S345F substitution, found in CTCL samples, is also located in the ridge region of the catalytic domain. Furthermore, based on a previous structural study, it was predicted that the specific region around this residue forms the autoinhibitory interface between cSH2 and the catalytic domain [29] . It can be inferred that the PLCγ1 S345F
substitution is likely to disrupt the autoinhibitory interface in a similar fashion to the immune disease-causing PLCγ2 D993L substitution in ALI5 mice.
The Y495C substitution in PLCγ2, which is found in mice with the ALI14 phenotype, leads to symptoms similar to those observed for ALI5 mice [14, 15] . Y495 is located in the beta-sheet in the spPH domain, which only in PLCγ2 binds Rac. In cells expressing Y495C variant, basal and Rac or EGFR-stimulated PLCγ2 activity was found to be increased. This observation, in combination with NMR and ITC studies,
illustrates that this substitution does not change the interaction between spPH and
Rac, but rather destabilizes the γSA and thereby contributes to overcome autoinhibition and facilitate activation [31] . It is possible that other cSH2-spPH interaction contacts could have a role in this context [29] . The recently discovered PLCγ1 S520F substitution in CTCL and to some extent also the PLCγ2 L845F substitution in ibrutinib-resistant CLL are spatially close to the ALI14 substitution, Y495C (Figure 2 ).
This suggests that these cancer-associated substitutions could both be activating PLCγ1 and PLCγ2 by destabilizing γSA, and consequently relieving auto-inhibition, as was found to be the case for the ALI14 substitution.
Deletions and single amino acid substitutions in PLCγ1 and PLCγ2 identified so far directly affect enzyme activity as a common functional outcome, further supporting genetic evidence for the link between these mutations and disease development.
Based on these findings, PLCγ enzymes should be further considered as a potential therapeutic target. Recent advances in studies of PLC enzyme, however, also highlighted some new important points that should be considered in future developments of PLC inhibitors.
Pharmacological inhibitors of PLC activity
The new findings support diverse, and sometime opposing roles of different PLC isoforms, in particular in cancer [20] [21] [22] [32] [33] [34] [35] [36] [37] , and indicate that the generation of isozyme-specific inhibitors is highly desirable. Nevertheless, recent studies of the gain-of-function mutations that affect auto-inhibitory surfaces ( Figure 2 ) would imply that active site of these variants can be more exposed and accessible, suggests the possibility that more general PLC inhibitors could also be effective.
Concluding remarks
The Table 1 . PLCγ mutations in immune disorders Table 2 . PLCγ mutations in cancer been discovered that PLCγ2 is also activated by the small GTPase Rac [40, 41] . by a phosphorylation independent mechanism (dotted arrow).
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Box 2. Developments of pharmacological inhibitors that target PLC enzymes.
Historically, the first attempts to develop pharmacological inhibitors against PLC were focused on the development of PIP 2 -based chemical probes that could be used as a substrate in screens and as lead compounds. Despite the initial difficulties, some promising, fluorogenic substrate analogues were reported [42] [43] [44] [45] PLCγ-specific array (γSA) PLC-core N--C
